Wealthstream Advisors Inc. Purchases 209 Shares of Johnson & Johnson (NYSE:JNJ)

Wealthstream Advisors Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 11.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,039 shares of the company’s stock after purchasing an additional 209 shares during the period. Wealthstream Advisors Inc.’s holdings in Johnson & Johnson were worth $333,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co increased its position in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P increased its position in Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. increased its position in Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares in the last quarter. Equitable Holdings Inc. increased its position in Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its position in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.3 %

Shares of NYSE JNJ opened at $173.43 on Tuesday. The stock has a market cap of $453.43 billion, a P/E ratio of 24.15, a P/E/G ratio of 3.28 and a beta of 0.56. The firm has a 50 day moving average price of $176.33 and a 200 day moving average price of $171.44. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the previous year, the firm posted $2.60 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Bank of America lowered their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Sanford C. Bernstein lowered their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $182.42.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at $18,864,202. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 300,750 shares of company stock valued at $52,311,677. 0.35% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.